<DOC>
	<DOCNO>NCT00843024</DOCNO>
	<brief_summary>This study design determine well combination medication , sumatriptan naproxen sodium , treat migraine headache adolescent 12-17 year old</brief_summary>
	<brief_title>Migraine Study Adolescent Patients</brief_title>
	<detailed_description>The purpose study determine whether combination product , sumatriptan naproxen sodium , effective compare placebo treatment acute migraine adolescent subject 12-17 year old . Subjects treat two migraine attack ~25 week period .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Subjects eligible enrollment study must meet following criterion : 1 . Subject &gt; /=12 year age &lt; /=17 year age Screening Visit . 2 . Subject migraine without aura ( ICHDII criterion , 1.2.1 1.1 ) . A history least two , eight attack per month , six month prior Screening Visit require . Attacks last minimum three hour associate moderatetosevere headache pain . 3 . Subject able distinguish migraine headache ( i.e. , tensiontype headache ) . 4 . Male female subject . Female subject eligible participation study : 1 . Females nonchildbearing potential ; 2 . Females childbearing potential , negative urine pregnancy test screening , agree use one GlaxoSmithKline ( GSK ) specify highly effective method avoid pregnancy 5 . Any subject take oral contraceptive enrollment must stable regimen least 2 month prior screen . 6 . Subject subject 's parent legal guardian able read write English Spanish . 7 . Subject able read , comprehend , complete subject diary . 8 . Subject 's parent legal guardian willing able provide Informed Consent prior subject entry study . 9 . Subject willing able provide Informed Assent prior entry study ( require ) . Subjects meet follow criterion must enrol study : 1 . Subject &lt; 74 pound ( 33.3 kg ) . 2 . Subject â‰¥15 headache day per month total ( migraine , probable migraine , tensiontype ) , retinal ( ICHDII 1.4 ) , basilar ( ICHDII 1.2.6 ) , hemiplegic migraine ( ICHDII 1.2.4 ) , secondary headache . 3 . Subject , investigator 's opinion likely unrecognized cardiovascular cerebrovascular disease . 4 . Subject uncontrolled hypertension screen take angiotensinconverting enzyme ( ACE ) inhibitor angiotensin receptor blocker . 5 . Subject history congenital heart disease , cardiac arrhythmia require medication , history clinically significant electrocardiogram abnormality , investigator 's opinion , contraindicate participation study . 6 . Subject evidence history ischemic vascular disease include : ischemic heart disease , ischemic abdominal syndrome , peripheral vascular disease , signs/symptoms consistent . 7 . Subject evidence history central nervous system pathology include stroke and/or transient ischemic attack ( TIAs ) , epilepsy structural brain lesion lower convulsive threshold , treat antiepileptic drug seizure control within 5 year prior screen . 8 . Subject history impair hepatic renal function , investigator 's opinion , contraindicate participation study . 9 . Subject hypersensitivity , allergy , intolerance , contraindication use triptan , NSAID , aspirin ( include sumatriptan naproxen preparation ) nasal polyps asthma . 10 . Subject use ergot medication previous three month migraine prophylaxis take medication stabilize ( i.e. , change dose within past 2 month ) either chronic intermittent migraine prophylaxis comorbid condition stabilize . 11 . Subject recent history regular use opioids barbiturates treatment migraine headache and/or nonmigraine pain . Regular use define average 4 day per month last 6 month . 12 . Subject take , plan take , monoamine oxidase inhibitor ( MAOI ) , include herbal preparation contain St. John 's Wort ( Hypericum perforatum ) , anytime within two week prior screen two week post treatment . 13 . Subject history bleed disorder currently take anticoagulant antiplatelet agent . 14 . Subject evidence history gastrointestinal surgery , GI ulceration , perforation past six month , gastrointestinal bleeding past year , evidence history inflammatory bowel disease . 15 . Subject pregnant , actively try become pregnant , breast feeding subject willing pregnancy test ( ) . 16 . Subject test positive illicit substance toxicology screen , evidence alcohol substance abuse within last year , concurrent medical psychiatric condition , investigator 's judgment , likely interfere study conduct , subject cooperation , evaluation interpretation study result , otherwise contraindicate participation clinical trial . 17 . Subject participate investigational drug trial within previous 4 week plan participate another study time study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Migraine without aura</keyword>
	<keyword>Migraine efficacy</keyword>
	<keyword>Migraine</keyword>
	<keyword>Migraine headache</keyword>
	<keyword>Adolescent migraine</keyword>
	<keyword>TREXIMET</keyword>
	<keyword>Sumatriptan succinate</keyword>
	<keyword>Naproxen sodium</keyword>
	<keyword>Migraine , acute</keyword>
</DOC>